A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients

Oncogene

Volumn 29, Issue 43, 2010, Pages 5796-5808

  Oram, S H ^a   Thoms, J A I ^b   Pridans, C ^a   Janes, M E ^b   Kinston, S J ^a   Anand, S ^a   Landry, J R ^c   Lock, R B ^d   Jayaraman, P S ^e   Huntly, B J ^a   Pimanda, J E ^b   Gottgens B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ChIP on chip; chromatin immunoprecipitation; human; leukaemia; LMO2; transcriptional regulation

Indexed keywords

TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FLI 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD CELL; CELL GROWTH; CHROMATIN; CONTROLLED STUDY; ENDOTHELIUM CELL; ENHANCER REGION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LMO2 ONCOGENE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; T ACUTE LYMPHOBLASTIC LEUKEMIA; TRANSCRIPTION REGULATION;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; METALLOPROTEINS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 78049346302     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.320     Document Type: Article

References (46)

1. Appert A, Nam CH, Lobato N, Priego E, Miguel RN, Blundell T et al. (2009). Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. Cancer Res 69: 4784-4790.
2. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P et al. (2004). Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood 104: 4173-4180.
3. Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD et al. (2006). High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24: 4714-4720.
4. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD et al. (2007). Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25: 3739-3745.
5. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. (1991). The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 88: 4367-4371.
6. Bohne A, Schlee C, Mossner M, Thibaut J, Heesch S, Thiel E et al. (2009). Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leuk Res 33: 817-822.
7. Chan WY, Follows GA, Lacaud G, Pimanda JE, Landry JR, Kinston S et al. (2007). The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl\-/\-phenotype. Blood 109: 1908-1916.
8. Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F et al. (2004). Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103: 2771-2778.
9. Crable SC, Anderson KP. (2003). A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene. Blood 101: 4757-4764.
10. Crist WM, Pui CH. (1993). Clinical implications of cytogenetic and molecular analyses of pediatric acute lymphoblastic leukemia. Stem Cells 11: 81-87.
11. Dave UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, Yi M et al. (2009). Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 5: e1000491.
12. Donaldson IJ, Chapman M, Kinston S, Landry JR, Knezevic K, Piltz S et al. (2005). Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet 14: 595-601.
13. Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA et al. (2004). Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 103: 1909-1911.
14. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. (2002). Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87.
15. Follows GA, Dhami P, Gottgens B, Bruce AW, Campbell PJ, Dillon SC et al. (2006). Identifying gene regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. Genome Res 16: 1310-1319.
16. Garand R, Bene MC. (1993). Incidence, clinical and laboratory features, and prognostic significance of immunophenotypic subgroups in acute lymphoblastic leukemia: the GEIL experience. Recent Results Cancer Res 131: 283-295.
17. 0 bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol 24: 1870-1883.
18. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
19. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. (2003a). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
20. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. (2003b). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
21. Hammond SM, Crable SC, Anderson KP. (2005). Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res 29: 89-97.
22. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
23. Huang X, Brown C, Ni W, Maynard E, Rigby AC, Oettgen P. (2006). Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 107: 3153-3160.
24. Kadrmas JL, Beckerle MC. (2004). The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 5: 920-931.
25. Kruse EA, Loughran SJ, Baldwin TM, Josefsson EC, Ellis S, Watson DK et al. (2009). Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc Natl Acad Sci 106: 13814-13819.
26. Landry JR, Bonadies N, Kinston S, Knezevic K, Wilson NK, Oram SH et al. (2009). Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. Blood 113: 5783-5792.
27. Landry JR, Kinston S, Knezevic K, Donaldson IJ, Green AR, Gottgens B. (2005). Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood 106: 2680-2687.
28. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, Wadman I et al. (1996). Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 15: 1021-1027.
29. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. (1995). The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 11: 853-862.
30. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M et al. (2002). The nonobese diabetic/severe combined immunodefi-cient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99: 4100-4108.
31. MacArthur BD, Ma'ayan A, Lemischka IR. (2009). Systems biology of stem cell fate and cellular reprogramming. Nat Rev Mol Cell Biol 10: 672-681.
32. McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH et al. (2010). The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 327: 879-883.
33. Noy P, Williams H, Sawasdichai A, Gaston K, Jayaraman P-S. (2010). PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling. Mol Cell Biol 30: 2120-2134.
34. Osada H, Grutz G, Axelson H, Forster A, Rabbitts TH. (1995). Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc Natl Acad Sci USA 92: 9585-9589.
35. Pimanda JE, Ottersbach K, Knezevic K, Kinston S, Chan WY, Wilson NK et al. (2007). Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci USA 104: 17692-17697.
36. Rabbitts TH, Axelson H, Forster A, Grutz G, Lavenir I, Larson R et al. (1997). Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis. Leukemia 11(Suppl 3): 271-272.
37. Raimondi SC. (2007). T-lineage acute lymphoblastic leukemia (T-ALL). Atlas Genet Cytogenet Oncol Haematol 11: 69-81.
38. Royer-Pokora B, Loos U, Ludwig WD. (1991). TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is over-expressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6: 1887-1893.
39. Royer-Pokora B, Rogers M, Zhu TH, Schneider S, Loos U, Bolitz U. (1995). The TTG-2/RBTN2T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL). Oncogene 10: 1353-1360.
40. Valge-Archer V, Forster A, Rabbitts TH. (1998). The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11). Oncogene 17: 3199-3202.
41. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG et al. (2008). Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 22: 124-131.
42. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A et al. (1997). The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 16: 3145-3157.
43. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. (1994). The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 78: 45-57.
44. Wilson NK, Miranda-Saavedra D, Kinston S, Bonadies N, Foster SD, Calero-Nieto F et al. (2009). The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryonic hematopoietic development. Blood 113: 5456-5465.
45. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. (1998). The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 95: 3890-3895.
46. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. (2002). Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143.